Cytochrome bc 1 is a proven drug target in the prevention and treatment of malaria. The rise in drug-resistant strains of Plasmodium falciparum, the organism responsible for malaria, has generated a global effort in designing new classes of drugs. Much of the design/redesign work on overcoming this resistance has been focused on compounds that are presumed to bind the Q o site (one of two potential binding sites within cytochrome bc 1 ) using the known crystal structure of this large membrane-bound macromolecular complex via in silico modeling. Cocrystallization of the cytochrome bc 1 complex with the 4(1H)-pyridone class of inhibitors, GSK932121 and GW844520, that have been shown to be potent antimalarial agents in vivo, revealed that these inhibitors do not bind at the Q o site but bind at the Q i site. The discovery that these compounds bind at the Q i site may provide a molecular explanation for the cardiotoxicity and eventual failure of GSK932121 in phase-1 clinical trial and highlight the need for direct experimental observation of a compound bound to a target site before chemical optimization and development for clinical trials. The binding of the 4(1H)-pyridone class of inhibitors to Q i also explains the ability of this class to overcome parasite Q o -based atovaquone resistance and provides critical structural information for future design of new selective compounds with improved safety profiles. malaria | cytochrome bc 1 | drug discovery | Plasmodium falciparum | membrane protein
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Cytochrome bc 1 (ubiquinol: cytochrome c oxidoreductase; complex III) is a major drug target for the treatment and prevention of malaria, and in the treatment of toxoplasmosis (8, 11) . Cytochrome bc 1 is a dimeric multisubunit electron transport protein embedded in the inner-mitochondrial membrane (12) (13) (14) . There are three catalytic subunits: cytochrome b, cytochrome c 1 , and the Rieske iron-sulfur protein, which are present in all bc 1 complexes (12) . The complex forms part of the respiratory chain and acts to transport H + into the intermembrane space through the oxidation and reduction of ubiquinone in the modified Q cycle (12, 15, 16) . The Q cycle requires two distinct binding sites for the reduction and oxidation of ubiquinol and ubiquinone. Both sites are located within cytochrome b; the Q o site acts to oxidize ubiquinol near the intermembrane space (17) , and the Q i site binds and reduces ubiquinone near the mitochondrial matrix. In P. falciparum, cytochrome bc 1 is essential to ensure a pool of oxidized ubiquinone for use by dihydroorotate dehydrogenase (DHODH) in pyrimidine biosynthesis; inhibition of cytochrome bc 1 or DHODH leads to parasite death (18, 19) . Atovaquone, a hydroxynapthoquinone ( Fig. 1) , binds cytochrome bc 1 at the Q o site (20, 21) . It is used as a fixed-dose combination with proguanil (marketed as Malarone) for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers. In the United States, between 2009 and 2011, Malarone prescriptions accounted for 70% of all antimalarial pretravel prescriptions (22) .
Several mutations, giving rise to atovaquone-resistant strains of P. falciparum and Toxoplasma gondii, have been reported since the turn of the century (23) (24) (25) (26) (27) . These mutations arise in the Q o pocket and prevent atovaquone from binding (28) . A recent X-ray structure of cytochrome bc 1 from Saccharomyces cerevisiae has shown atovaquone bound in the catalytic Q o site, offering explanation for the cross-species resistance (20) . Many different classes of compound have been investigated as potential drugs and much work has focused on inhibition of the Q o site (23, (29) (30) (31) (32) . The 4(1H)-pyridones have been researched for their antimalarial properties since the 1960s, based on the compound clopidol (33, 34) (Fig. 1) . GW844520 produced by GlaxoSmithKline (GSK) was found to have excellent antimalarial drug properties, even against Significance X-ray crystallography greatly benefits drug discovery work by elucidating information about the binding of drug compounds to their target. Using this information, changes to the compounds can be made in a process known as rational drug design. Cytochrome bc 1 is a proven drug target in the treatment and prevention of malaria, a disease that kills over half a million people each year and many compounds have been developed to inhibit cytochrome bc 1 . Here we show the binding of two such compounds in X-ray crystal structures, which reveal an unexpected binding site. This work opens up a new area for antimalarial research and reinforces the need for structural information in drug design.
atovaquone-resistant parasites, but had to be withdrawn from development due to unexpected toxicity (35) . GSK932121 was also found to have strong antimalarial properties, including against atovaquone-resistant parasites (36) , and progressed to a first time in human (FTIH) study. However, during the FTIH study, a phosphate-prodrug backup of GSK932121 was observed to result in unexpected acute toxicity in rats after oral administration, which was subsequently replicated by dosing GSK932121 alone through i.p. administration at similar exposure levels to those achieved with its prodrug. The observed acute toxicity resulted in the immediate termination of the FTIH study and was attributed to cardiotoxicity, possibly via the inhibition of the mammalian bc 1 (37) . It was concluded that these compounds may bind to the Q o site of cytochrome bc 1 in a novel way to overcome atovaquone resistance.
The Q i site of cytochrome bc 1 has been far less explored in the search for antimalarial compounds and only the binding of a few compounds has been visualized directly (38) (39) (40) . Several compounds have been suggested to bind the Q i site, including potential antimalarial compounds, but due to lack of structural information have not been pursued vigorously (41) . Here we provide the structure of bovine heart cytochrome bc 1 complex with 4(1H)-pyridone compounds, GW844520 and GSK932121. The crystallographic structures provide clear evidence of these compounds unexpectedly bound in the Q i site. This discovery explains the ability of this class to overcome parasite atovaquone resistance and provides critical structural information for the future design of new selective compounds with reduced/no toxicity.
Results
The Pyridones GSK932121 and GW844520 Bind to Q i Site of Cytochrome bc 1 . Structures of cytochrome bc 1 complexes from multiple organisms bound to various compounds have been previously published (14, 38, 42, 43) . The majority of these compounds are bound to the Q o site in various conformations (44) . The pyridones GSK932121 and GW844520 had been suggested to bind bovine cytochrome bc 1 at the Q o site through mutation and chemicalbinding studies (29) . Electron density was clearly visible within the Q i site and each of the pyridones fit accurately (Fig. 2) . The Q i binding site is located within the transmembrane region of cytochrome bc 1 and is formed by residues of transmembrane helices A, D, and E as well as helix a and the heme b H (14, 45) . It is accessible through a hydrophobic channel, which terminates at heme b H and several polar residues (Fig. 3) . The binding of both GSK932121 and GW844520 appears very similar with the head group of both molecules binding close to heme b H and the tail extending out of the channel away from the heme (Fig. 3C) .
The head of the compound was placed unambiguously in a plane according to the omit Fo-Fc density and oriented so that the amine of the pyridone and the N of His201 on helix D (Fig.  2) were within bonding range. The carbonyl of both GW844520 and GSK932121 was within 3.5 Å of both Ser35 on loop A and OD1 of Asp228 on loop E to allow forming of H bonds (Fig. 3C ). After refinement with the compounds, additional electron density became visible, allowing positioning of the triflouromethyl tail group between Met190 and Met194. There was visible density along the first phenyl group of the hydrophobic tail of each compound. Residues Phe18, Leu21, and Leu197 form a tight hydrophobic pocket around the aromatic rings of the pyridone tail while Phe220 appears to form a stacking interaction with the head group suggesting hydrophobic interactions provide a large part of the binding energy (Fig. 3C) . No density was visible in the Q o site confirming that these compounds bind solely to the Q i site.
Residue Differences in Binding Pocket. The protein sequence alignment of bovine, human, and P. falciparum cytochrome b shows a fairly conserved Q i binding site (Fig. 4C) . However, there are differences in the N-terminal region of cytochrome b between the mammalian protein and the Plasmodium homolog. The protein is shorter in both T. gondii and Plasmodia. Both Phe18 and Leu21 of the surface loop before helix A, which forms a hydrophobic pocket around the aromatic tail of the 4(1H)-pyridones, are replaced with Leu and Tyr, respectively, in both P. Clopidol is a known treatment for malaria and is the basis for the pyridone class of compound, including GW844520 and GSK932121. GSK932121 has a substituted alkyl group located on the head compared with GW844520. falciparum and T. gondii, which would suggest large differences in the binding around the tail groups of both compounds. Ala191 allows a large opening in the cavity toward the terminus of the Q i site but is replaced by a Cys residue in the parasite. Both Met190 and Met194 are nonconserved between all of the sequences aligned, whereas Gly204 and Ser205 are conserved. Ser205 has been shown to be involved in the binding of ubiquinone (44) . Phe220 is conserved across cytochrome b sequences and is thought to be important in forming an interaction with the aromatic pyridone head group, whereas Leu201 located on the opposite side to Phe220 is conserved in both the parasite and human protein.
Cellular Toxicity of GW844520 and GSK932121 Is Associated with Mitochondrial Dysfunction. Mitochondrial toxicity can be identified by the differing responses observed for HepG2 cells grown in glucose-containing media, which favors glycolysis, or galactosecontaining media, which promotes reliance upon oxidative phosphorylation (46) . As an exemplar, the toxicity of tamoxifen is observed to be unaltered by a change of growth media, as is expected for a compound with no known mitochondrial toxicity (Fig. 5A) . Conversely, the mitochondrial complex I (NADH: quinone oxidoreducatse) inhibitor rotenone is not significantly toxic in glucose media but demonstrates severe toxicity in galactose media (Fig. 5B) , thus indicting disruption of oxidative phosphorylation. Both GW844520 and GSK932121 (Fig. 5 C and D) displayed significantly enhanced toxicity in the galactose medium, indicative of mitochondrial-based toxicity. However, the next generation 4(1H)-quinolone-3-diarylether ELQ 300 (30) and 2-aryl quinolone SL-2-25 (47) did not show significant enhancement of toxicity in galactose-grown HepG2 (Fig. 5 E and F) .
Molecular Docking. Molecular docking was performed using the coordinates of the cocrystallized structures of bovine bc 1 complex reported here. A protocol was developed and validated, which is able to reproduce the crystallographic binding modes of both GW844520 and GSK932121 (Fig. 6 ). The docked model and experimental structures showed excellent agreement (rmsd < 2 Å) for both GSK932121 and GW844520 (Fig. 6) . This protocol was also applied to predict the binding poses for antimycin A, a compound known to bind to the Q i site, as a control (42) . Atovaquone that has been shown not to bind to the Q i site was also used as a control. The docking for antimycin A was able to reproduce the X-ray crystallographic binding pose (rmsd 1.67 Å) and forms a very similar array of noncovalent interactions with the protein as GSK932121 and GW844520. In contrast, atovaquone did not produce consistent docking poses in the Q i binding site (data not shown). These facts indicate the robust nature of the docking protocol used in the light of new structures and show the potential for its use for further development of compounds. The next generation compounds, namely ELQ 300 and SL-2-25, showed their binding to the Q i site.
Discussion
The structural details of cocrystallized bovine cytochrome bc 1 complex and compounds GW844520 and GSK932121 show similar binding modes in the Q i pocket (Fig. 2) , suggesting that this binding mode is likely to prevail in the family of 4(1H)-pyridone compounds. The formation of hydrogen bonds between several residues and the head group of each compound means that these are strongly bound at the end of the channel, 12 Å away from the center of heme b H . The head forms several electrostatic interactions. Ne2 of His201 is pointed directly at the amide of the pyridone head and is separated by 3.3 Å. Ser205 and Asp228 on helix E are 2.9 Å and 2.7 Å from the carbonyl group, respectively, which is common among many Q i binding ligands. These residues are also found to interact directly with the head of antimycin and ubiquinone, which lie in a similar position deep within this cavity (38, 42) . The chlorine atom is 4.3 Å away from the carboxyl of Trp31 and is largely surrounded by aliphatic residues in a hydrophobic space. The change from a methyl group at position 6 in GW844520 to an alkyl group in GSK932121 shows little difference in the electron density; however, it does appear within 3 Å of the carbonyl of the peptide bond in Ala17. Ala17 forms part of the N-terminal region that Fig. 3 . Binding of GW844520 and GSK932121 within the hydrophobic Q i cavity. (A) Surface view of cytochrome bc 1 in complex with GSK932121 (green) and GW844520 (yellow) colored by hydrophobicity: more hydrophobic residues are red, more polar residues are white. (B) View of the binding site: the hydrophobic tail of each compound lies along the cavity, keeping close to the hydrophobic surface, whereas the head binds near the heme in a polar environment. (C) Two-dimensional pharmacophore of the various interactions between the Q i binding site and both pyridone compounds: GW844520 in the foreground, GW844520 in gray in the rear. Specific atoms are colored accordingly: carbon in black, oxygen in red, nitrogen in blue, and halogens in green (produced using Ligplot) (53) . is not conserved in Plasmodia parasites (Fig. 4) , which may help to explain differences in binding between mammalian and parasite complexes. The tail of each compound proceeds away from heme b H and directly down toward the entrance of the cavity between cytochrome bc 1 monomers. The tail region appears more flexible in GSK932121, perhaps due to alternate location of the trifluoromethyl group (Fig. 1 ) no longer being able to interact with Met194. Phe18 can be seen forming a stacking interaction with both phenyl rings of the tail, which may help fix the pyridone compounds in place as opposed to the lack of density that was seen in ubiquinone-bound structures (38) . This would help explain the increased strength of binding in the pyridones compared with ubiquinone.
Reversing the Crabtree effect in HepG2 cells by switching to a galactose carbon source can be shown to clearly discriminate between nonmitochondrial (e.g., tamoxifen; Fig. 5A ) and mitochondrial (e.g., rotenone; Fig. 5B ) inhibitors. Consistent with the presented cocrystallized structural data of GSK932121 and GW844520 bound to bovine bc 1 and the hypothesis that the acute in vivo toxicity seen in this pyridone class is of mitochondrial origin (37), both GSK932121 and GW844520 display significantly enhanced toxicity in galactose media (Fig. 5 C and D) . The next generation 4(1H)-quinolone-3-diarylether ELQ 300 (30) and 2-aryl quinolone SL-2-25 (47) did not show significant enhancement of toxicity in galactose-grown HepG2 (Fig. 5 E and  F) , suggesting that these preferentially target Plasmodium bc 1 .
These data are consistent with human and bovine bc 1 sensitivity data previously reported (30, 47) .
As noted, it has been generally accepted that the 4(1H)-pyridone class, e.g., GW844520, targets the Q o oxidation site of the bc 1 complex, via analogy with the mechanism of action of the Q o targeted antimalarial atovaquone, and indeed models of the pyridone/bc 1 Q o interaction of these molecules have been previously described (33) . The next generation bc 1 inhibitor quinolone, ELQ 300, was designed by replacement of the pyridone unit of GW844520, with a quinolone group as shown (Fig. 1) , and the close similarity of these two antimalarials would suggest, based on the GSK model, that the Q o site is the likely molecular target. Here, using docking, we show that ELQ 300 and SL-2-25 bind well at the Q i site, suggesting an alternative target site/ mechanism to atovaquone.
This modeling observation is consistent with our recent studies on the quinolone 1-hydroxy-2-dodecyl-4(1H)quinolone (HDQ) in yeast models (41) . Introduction of point mutations into the Q i site, namely G33A, H204Y, M221Q, and K228M, markedly decreased HDQ inhibition; by contrast, known inhibitor resistance mutations at the Q o site did not cause HDQ resistance. A recent study in T. gondii showed that mutations at the Q i site of yeast cytochrome b reduced the growth inhibition effect of ELQ 271 (48) . Taken together, these data indicate that the Q i site of the bc 1 complex is the likely target for a number of next generation ubiquinone-mimicking antimalarials that are not cross-resistant with atovaquone. In support of this finding, the docking poses of both ELQ 300 and SL-2-25 molecules were similar, with the quinolone head groups both bound at the end of the pocket defined by His201, Ser205, Asp228, and Ser35 of cytochrome b with the long hydrophobic tails of the compounds directed toward the region defined by Met190, Met194, and Ile42 (analogous with GSK932121 and GW844520).
Although cytochrome b appears to be highly conserved across phyla, the differences between cytochrome b in members of the Plasmodia family compared with human appear significant from sequence alignment. The N-terminal region appears considerably shorter, which is likely to result in a considerably different opening to the Q i cavity and binding site. This difference in primary structure could open up the tail region of the pyridone compounds to more specific binding, preventing cross-reactivity between pathogen and host. Interestingly, the fluorine atom of GW844520 appears bound next to Met194, which is only present in the bovine cytochrome b protein. This could explain the higher IC 50 reported for bovine cytochrome bc 1 compared with the human (29) , despite the high conservation in their sequence. In the Plasmodia protein, Met194 is substituted by a Phe residue (Fig. 4C) , which could allow for specific compound modifications to be made to increase binding. Phe18 is another promising tail region residue for drug design, as in the Plasmodia sequence, it is substituted for a Leu. Within the head group of the binding site, Ser205, which binds the carbonyl of both pyridone molecules, is replaced with a Phe residue. It is difficult to estimate what would happen within the binding site, but this difference may go some way to explaining why binding within the parasite is an order of magnitude stronger than in bovine (29) .
Work on improving the clinically promising 4(1H)-pyridones so far has lacked structural information (33, 34) . The elucidation of 4(1H)-pyridone binding within the Q i site of mitochondrial cytochrome bc 1 complex provides for the first time to our knowledge an opportunity for rational drug design to increase selectivity against Plasmodia parasites toward novel treatments and reducing transmission. The overwhelming importance of direct observation of drug leads at their target sites is highlighted in this study. In situ visualization of drug candidates by experimental structural methods such as X-ray crystallography should be built in as the gold standard for validation of binding of these compounds before optimization in a drug-discovery pipeline.
Materials and Methods
Preparation of Crude Protein. Isolation of crude mitochondria was carried out as previously reported in the following method (14) . Briefly, bovine heart muscle was homogenized in a Waring blender and added at a ratio of 2 L buffer (250 mM sucrose; 20 mM K 2 HPO 4 ; 2 mM succinic acid; 0.5 mM EDTA) per 500 g of muscle tissue. The homogenate was subjected to centrifugation at 1,500 × g for 20 min and the supernatant was then further centrifuged at 23,500 × g for 20 min. The pellet, containing bovine mitochondria, was collected and washed in wash buffer 1 (50 mM KPi pH 7.5; 0.1 mM PMSF). The mitochondrial pellet was resuspended in wash buffer 2 (50 mM KPi pH 7.5; 250 mM NaCl; 3 mM NaN 3 ; 0.1 mM PMSF). The amount of protein was quantified using a BCA (bicinchoninic acid) assay (Pierce). The remaining solution was centrifuged at 180,000 × g for 60 min and the pellet was resuspended in the same wash buffer, with the addition 0.1 mg n-dodecyl β-Dmaltopyranoside (DDM) per 1 mg of protein. The solution was centrifuged again under the same conditions. The pellet was then resuspended with the addition of 0.9 mg DDM per 1 mg of protein and centrifuged under the same conditions once more. The supernatant containing solubilized membrane proteins was collected.
Purification of Cytochrome bc 1 . The solubilized proteins were loaded on a DEAE-Sepharose CL-6B (Sigma-Aldrich) column (approximately 50 mL) preequilibrated with buffer A (50 mM KPi pH 7.5; 250 mM NaCl; 0.03% DDM; 3 mM NaN 3 ), then washed with 2 column volumes (CVs) of buffer A and eluted along a linear gradient from 250 mM to 500 mM NaCl. The cytochrome bc 1 -containing fractions were pooled together before being diluted twofold with buffer C (50 mM KPi pH 7.5; 0.03% DDM; 3 mM NaN 3 ). The protein solution was then applied to a hydroxyapatite (Bio-Rad) column (approximately 15 mL), washed with 10 CVs of buffer C before elution with the gradient from 50 mM to 1 M KPi (pH 7.5). Fractions containing cytochrome bc 1 were then concentrated to approximately 500 μL, using an Amicon Ultra-15 (Millipore, MWCO 100,000). The concentrated protein was then applied to a Sephacryl-S300 (GE Healthcare) column (approximately 120 mL) preequilibrated with buffer D (25 mM KPi (pH 7.5); 100 mM NaCl; 0.015% DDM; 3 mM NaN 3 ) and eluted at a flow rate of 0.5 mL/min.
Crystallization of Cytochrome bc 1 . Inhibitors dissolved in DMSO solution at a stock concentration of 10 mM were added to cytochrome bc 1 in 10-fold molar excess and incubated at 4°C for one hour. Remaining DMSO and inhibitors were removed via buffer exchange on an Amicon Ultra-4 (Millipore, MWCO 100,000) and the protein was concentrated to 30 mg/mL in 25 mM KPi (pH 7.5), 100 mM NaCl, 0.015% DDM, 3 mM NaN 3 . Crystallization was preformed at 4°C by sitting drop vapor diffusion method over reservoir solution containing 50 mM KPi (pH 6.4-7.2), 100 mM NaCl, 3 mM NaN 3 , 10-13% PEG4000 and 0.14% 6-O-(N-Heptylcarbamoyl)-methyl-α-D-glucopyranoside (HECAMEG). Drops were made to 10 μL with 1:1 ratio of protein to precipitant. Crystals appeared overnight among precipitation and were allowed to grow before being flash frozen in 25% (vol/vol) glycerol.
Data Collection, Processing, Model Building, and Refinement. Data collection statistics can be found in Table 1 . Multiple crystals from the same drop were tested at 100 K using a home source FRE+ and Mar225 CCD at the Barkla X-ray Laboratory in Liverpool before transport to SOLEIL PROXIMA1 and Diamond Light Source IO4 beamline. Datasets from multiple crystals belonging to the same P6 5 space group and unit cell were collected at 100 K using a 1-Å beam before being scaled and merged together using DENZO in the HKL2000 suite (49). Molecular replacement was carried out using pdb: 1PPJ as a starting model (42) in MOLREP (50) followed by rigid body refinement in Refmac5 (51) . Cycles of automatic refinement were carried out using Refmac 5 with Prosmart restraints and manual input was done with COOT (52) . Ligands were produced in JLigand and added manually (53) . Pyridones were placed in both Q i sites of the dimer with equal confidence. Two-dimensional pharmacophores of both GSK932121 and GW844520 were produced using LigPlot+ (54) .
Sequence Alignment. Protein sequences for cytochrome b of various species were taken from the UniProtKB and aligned using ClustalOmega (55) . The alignment was visualized using JalView 2.8 and additional annotations were added using GIMP.
Reverse Crabtree-Effect Cellular Toxicity Studies. Cellular toxicities were determined based on the method of Marroquin et al. (46) modified by Warman et al. (56) , Briefly, HepG2 cells cultured in glucose media (high-glucose DMEM containing 25 mM glucose, 1 mM sodium pyruvate, 5 mM Hepes, 10% FBS, and 100 μg/mL penicillin/streptomycin) or galactose media (as per glucose media but using glucose-free DMEM) were added to 96-well plates (100 μL, 1 × 10 4 cells per well) and incubated for 24 h at 37°C. The test compounds were added and incubation continued for an additional 24 h. The plates were subsequently incubated for 2 h in the presence of 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution. Solubilization buffer, consisting of 50% (vol/vol) N,N-dimethylformamide and 20% (wt/vol) SDS, was added before well absorbance at 560 nm was measured using a Varioskan plate reader (Thermo Scientific). Experiments were performed in triplicate and repeated on three or more independent occasions. The IC 50 values were determined using a four-parameter logistic function.
Chemistry. ELQ 300 was prepared as described by Nilsen et al. using (4-(trifluoromethoxy) phenyl) boronic acid as starting material (57) . GW844520 was prepared as outlined by Yeates et al. (34) . GSK932121 was prepared in six steps from intermediate 2, according to Bueno et al. (33) . (For the synthesis of 2, see the route developed by Liu et al. (58) .
Molecular Docking. Three-dimensional structures of the compounds docked were created via energy minimization using the Merck molecular force field June 30, 14) . All molecular docking was performed using the GOLD docking suite version 5.2 (60) (61) (62) . A genetic algorithm (GA) using piecewise linear potential (PLP) as the fitness function was used for all docking calculations. Ten independent GA runs were performed for each ligand. Default settings were used except the "allow early termination" setting in the "fitness and search option" was turned off.
